Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Alvimopan for the Prevention of Postoperative Ileus in Inflammatory Bowel Disease Patients.

Jang J, Kwok B, Zhong H, Xia Y, Grucela A, Bernstein M, Remzi F, Hudesman D, Chen J, Axelrad J, Chang S.

Dig Dis Sci. 2019 Sep 14. doi: 10.1007/s10620-019-05839-5. [Epub ahead of print]

PMID:
31522323
2.

Hormone Therapy for Cancer Is a Risk Factor for Relapse of Inflammatory Bowel Diseases.

Axelrad JE, Bazarbashi A, Zhou J, Castañeda D, Gujral A, Sperling D, Glass J, Agrawal M, Hong S, Lawlor G, Hudesman D, Chang S, Shah S, Yajnik V, Ananthakrishnan A, Khalili H, Colombel JF, Itzkowitz S; New York Crohn’s and Colitis Organization.

Clin Gastroenterol Hepatol. 2019 Jul 11. pii: S1542-3565(19)30735-9. doi: 10.1016/j.cgh.2019.06.042. [Epub ahead of print]

PMID:
31302306
3.

IFN-I and IL-22 mediate protective effects of intestinal viral infection.

Neil JA, Matsuzawa-Ishimoto Y, Kernbauer-Hölzl E, Schuster SL, Sota S, Venzon M, Dallari S, Galvao Neto A, Hine A, Hudesman D, Loke P, Nice TJ, Cadwell K.

Nat Microbiol. 2019 Oct;4(10):1737-1749. doi: 10.1038/s41564-019-0470-1. Epub 2019 Jun 10.

PMID:
31182797
4.

Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes.

Koliani-Pace JL, Singh S, Luo M, Hirten R, Aniwan S, Kochhar G, Chang S, Lukin D, Gao Y, Bohm M, Swaminath A, Gupta N, Shmidt E, Meserve J, Winters A, Chablaney S, Faleck DM, Yang J, Huang Z, Boland BS, Shashi P, Weiss A, Hudesman D, Varma S, Fischer M, Sultan K, Shen B, Kane S, Loftus EV, Sands BE, Colombel JF, Sandborn WJ, Lasch K, Siegel CA, Dulai PS.

Inflamm Bowel Dis. 2019 Oct 18;25(11):1854-1861. doi: 10.1093/ibd/izz071.

5.

Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.

Faleck DM, Winters A, Chablaney S, Shashi P, Meserve J, Weiss A, Aniwan S, Koliani-Pace JL, Kochhar G, Boland BS, Singh S, Hirten R, Shmidt E, Kesar V, Lasch K, Luo M, Bohm M, Varma S, Fischer M, Hudesman D, Chang S, Lukin D, Sultan K, Swaminath A, Gupta N, Siegel CA, Shen B, Sandborn WJ, Kane S, Loftus EV Jr, Sands BE, Colombel JF, Dulai PS, Ungaro R.

Clin Gastroenterol Hepatol. 2019 Nov;17(12):2497-2505.e1. doi: 10.1016/j.cgh.2018.12.040. Epub 2019 Jan 6.

6.

Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.

Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, Chilukuri P, Koliani-Pace J, Winters A, Katta L, Shmidt E, Hirten R, Faleck D, Parikh MP, Whitehead D, Boland BS, Singh S, Sagi SV, Fischer M, Chang S, Barocas M, Luo M, Lasch K, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Shen B, Kane S, Loftus EV, Siegel CA, Sands BE, Colombel JF, Sandborn WJ, Dulai PS.

Am J Gastroenterol. 2018 Dec;113(12):696. doi: 10.1038/s41395-018-0401-4.

7.

Escalation of Immunosuppressive Therapy for Inflammatory Bowel Disease Is Not Associated With Adverse Outcomes After Infection With Clostridium difficile.

Lukin DJ, Lawlor G, Hudesman DP, Durbin L, Axelrad JE, Passi M, Cavaliere K, Coburn E, Loftus M, Jen H, Feathers A, Rosen MH, Malter LB, Swaminath A; IBD-ReMEdY Study (Research, Mentoring, Education New York).

Inflamm Bowel Dis. 2019 Mar 14;25(4):775-781. doi: 10.1093/ibd/izy308.

PMID:
30312400
8.

Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases.

Meserve J, Aniwan S, Koliani-Pace JL, Shashi P, Weiss A, Faleck D, Winters A, Chablaney S, Kochhar G, Boland BS, Singh S, Hirten R, Shmidt E, Hartke JG, Chilukuri P, Bohm M, Sagi SV, Fischer M, Lukin D, Hudesman D, Chang S, Gao Y, Sultan K, Swaminath A, Gupta N, Kane S, Loftus EV Jr, Shen B, Sands BE, Colombel JF, Siegel CA, Sandborn WJ, Dulai PS.

Clin Gastroenterol Hepatol. 2019 Jul;17(8):1533-1540.e2. doi: 10.1016/j.cgh.2018.09.035. Epub 2018 Sep 27.

9.

Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.

Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, Chilukuri P, Koliani-Pace J, Winters A, Katta L, Shmidt E, Hirten R, Faleck D, Parikh MP, Whitehead D, Boland BS, Singh S, Sagi SV, Fischer M, Chang S, Barocas M, Luo M, Lasch K, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Shen B, Kane S, Loftus EV, Siegel CA, Sands BE, Colombel JF, Sandborn WJ, Dulai PS.

Am J Gastroenterol. 2018 Sep;113(9):1345. doi: 10.1038/s41395-018-0162-0. Epub 2018 Jun 27. Erratum in: Am J Gastroenterol. 2018 Dec;113(12):1912.

10.

Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.

Dulai PS, Boland BS, Singh S, Chaudrey K, Koliani-Pace JL, Kochhar G, Parikh MP, Shmidt E, Hartke J, Chilukuri P, Meserve J, Whitehead D, Hirten R, Winters AC, Katta LG, Peerani F, Narula N, Sultan K, Swaminath A, Bohm M, Lukin D, Hudesman D, Chang JT, Rivera-Nieves J, Jairath V, Zou GY, Feagan BG, Shen B, Siegel CA, Loftus EV Jr, Kane S, Sands BE, Colombel JF, Sandborn WJ, Lasch K, Cao C.

Gastroenterology. 2018 Sep;155(3):687-695.e10. doi: 10.1053/j.gastro.2018.05.039. Epub 2018 May 30.

11.

The nocebo effect and patient perceptions of biosimilars in inflammatory bowel disease.

Pineles D, Malter L, Liang PS, Arsuaga A, Bosworth B, Hudesman DP, Chang S.

Eur J Clin Pharmacol. 2018 Oct;74(10):1361-1362. doi: 10.1007/s00228-018-2492-7. Epub 2018 May 31. No abstract available.

PMID:
29855655
12.

Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease.

Shmidt E, Kochhar G, Hartke J, Chilukuri P, Meserve J, Chaudrey K, Koliani-Pace JL, Hirten R, Faleck D, Barocas M, Luo M, Lasch K, Boland BS, Singh S, Vande Casteele N, Sagi SV, Fischer M, Chang S, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Kane S, Loftus EV Jr, Sandborn WJ, Siegel CA, Sands BE, Colombel JF, Shen B, Dulai PS.

Inflamm Bowel Dis. 2018 Oct 12;24(11):2461-2467. doi: 10.1093/ibd/izy171.

13.

Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Major Abdominal Operations for Inflammatory Bowel Disease: Retrospective Multicenter Cohort Study.

Lightner AL, Mathis KL, Tse CS, Pemberton JH, Shen B, Kochhar G, Singh A, Dulai PS, Eisenstein S, Sandborn WJ, Parry L, Stringfield S, Hudesman D, Remzi F, Loftus EV Jr.

Inflamm Bowel Dis. 2018 Mar 19;24(4):871-876. doi: 10.1093/ibd/izx076. Erratum in: Inflamm Bowel Dis. 2018 Nov 29;24(12):2657.

PMID:
29509927
14.

Integrated Analysis of Biopsies from Inflammatory Bowel Disease Patients Identifies SAA1 as a Link Between Mucosal Microbes with TH17 and TH22 Cells.

Tang MS, Bowcutt R, Leung JM, Wolff MJ, Gundra UM, Hudesman D, Malter LB, Poles MA, Chen LA, Pei Z, Neto AG, Abidi WM, Ullman T, Mayer L, Bonneau RA, Cho I, Loke P.

Inflamm Bowel Dis. 2017 Sep;23(9):1544-1554. doi: 10.1097/MIB.0000000000001208.

15.

Receptive Anal Intercourse in Patients with Inflammatory Bowel Disease: A Clinical Review.

Martin T, Smukalla SM, Kane S, Hudesman DP, Greene R, Malter LB.

Inflamm Bowel Dis. 2017 Aug;23(8):1285-1292. doi: 10.1097/MIB.0000000000001186. Review.

PMID:
28708804
16.

The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium.

Dulai PS, Singh S, Jiang X, Peerani F, Narula N, Chaudrey K, Whitehead D, Hudesman D, Lukin D, Swaminath A, Shmidt E, Wang S, Boland BS, Chang JT, Kane S, Siegel CA, Loftus EV, Sandborn WJ, Sands BE, Colombel JF.

Am J Gastroenterol. 2016 Aug;111(8):1147-55. doi: 10.1038/ajg.2016.236. Epub 2016 Jun 14.

PMID:
27296941
17.

Disease monitoring in inflammatory bowel disease.

Chang S, Malter L, Hudesman D.

World J Gastroenterol. 2015 Oct 28;21(40):11246-59. doi: 10.3748/wjg.v21.i40.11246. Review.

18.

Capsule endoscopy in Crohn's disease: are we seeing any better?

Hudesman D, Mazurek J, Swaminath A.

World J Gastroenterol. 2014 Sep 28;20(36):13044-51. doi: 10.3748/wjg.v20.i36.13044. Review.

19.

Risk of extraintestinal solid cancer with anti-TNF therapy in adults with inflammatory bowel disease: review of the literature.

Hudesman D, Lichtiger S, Sands B.

Inflamm Bowel Dis. 2013 Mar;19(3):644-9. doi: 10.1097/MIB.0b013e318280ebbd. Review.

PMID:
23314243
20.

Adalimumab for ulcerative colitis: ultra or just mediocre.

Hudesman D.

Inflamm Bowel Dis. 2013 Jan;19(1):217-8. doi: 10.1002/ibd.23015. No abstract available.

PMID:
23292352
21.

Adalimumab for Ulcerative Colitis: Ultra or Just Mediocre.

Hudesman D.

Inflamm Bowel Dis. 2013 Jan 3. [Epub ahead of print] No abstract available.

PMID:
23282581
22.

Detection of esophageal varices using CT and MRI.

Lipp MJ, Broder A, Hudesman D, Suwandhi P, Okon SA, Horowitz M, Clain DJ, Friedmann P, Min AD.

Dig Dis Sci. 2011 Sep;56(9):2696-700. doi: 10.1007/s10620-011-1660-8. Epub 2011 Mar 6.

PMID:
21380758
23.

Darkness and near work: myopia and its progression in third-year law students.

Loman J, Quinn GE, Kamoun L, Ying GS, Maguire MG, Hudesman D, Stone RA.

Ophthalmology. 2002 May;109(5):1032-8.

PMID:
11986114

Supplemental Content

Loading ...
Support Center